| Time After Starting | Time After Stopping | ALT* (U/L) | Bilirubin* (mg/dL) | HCV RNA (IU/mL) | HBV DNA (IU/mL) | Other |
|---|---|---|---|---|---|---|
| Pre | 0 | 62 | 0.7 | 2300 | INR 1.05 | |
| Day 0 | 0 | 60 | 0.9 | 1.3 million | HCV therapy started | |
| Week 2 | 0 | 30 | 0.5 | 26 | ||
| Week 4 | 0 | 30 | 0.5 | None | ||
| Week 7 | 0 | Symptomatic | ||||
| Week 8 | 0 | 1495 | 12.2 | None | Therapy stopped, INR 1.96 | |
| Week 9 | Week 1 | 950 | 19.0 | 22 million | Tenofovir/emtricitabine | |
| Week 10 | Week 2 | 375 | 13.0 | None | ||
| Week 12 | Week 4 | 110 | 3.0 | None | 1000 | |
| Week 13 | Week 5 | 70 | ||||
| Week 15 | Week 7 | 30 | 1.5 | None | 100 | |
| Week 28 | Week 18 | 30 | 0.5 | None | None | |
| Normal Values | <40 | <1.2 | None | None | ||
Some values estimated from Figure 1.
From: Sofosbuvir
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.